- Conditions
- HIV, HIV Infections
- Interventions
- E/C/F/TAF
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 252 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2018
- U.S. locations
- 51
- States / cities
- Phoenix, Arizona • Little Rock, Arkansas • Beverly Hills, California + 40 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1273–1296
of 7,459
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Astrocytoma, Oligodendroglioma
- Interventions
- Vorasidenib, Pembrolizumab
- Drug
- Lead sponsor
- Institut de Recherches Internationales Servier
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 17
- States / cities
- Birmingham, Alabama • Los Angeles, California • San Francisco, California + 12 more
- Conditions
- Optim Lead Insulation Related Adverse Events
- Interventions
- Not listed
- Lead sponsor
- Abbott Medical Devices
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 14,124 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2020
- U.S. locations
- 245
- States / cities
- Alabaster, Alabama • Fort Payne, Alabama • Gadsden, Alabama + 189 more
- Conditions
- Spinal Muscular Atrophy
- Interventions
- Risdiplam
- Drug
- Lead sponsor
- Genentech, Inc.
- Industry
- Eligibility
- Not listed
- Enrollment
- 403 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 37
- States / cities
- Phoenix, Arizona • Little Rock, Arkansas • Loma Linda, California + 31 more
- Conditions
- Prader-Willi Syndrome, Obesity
- Interventions
- ZGN-440 for Injectable Suspension, ZGN-440 Placebo for Injectable Suspension
- Drug
- Lead sponsor
- Zafgen, Inc.
- Industry
- Eligibility
- 12 Years to 65 Years
- Enrollment
- 108 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 15
- States / cities
- Sacramento, California • San Diego, California • Aurora, Colorado + 12 more
- Conditions
- Epilepsy, Dravet Syndrome (DS), Lennox-Gastaut Syndrome (LGS)
- Interventions
- Soticlestat
- Drug
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 2 Years and older
- Enrollment
- 156 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2025
- U.S. locations
- 27
- States / cities
- Phoenix, Arizona • Los Angeles, California • Aurora, Colorado + 18 more
- Conditions
- Sarcoma
- Interventions
- dactinomycin, busulfan, doxorubicin hydrochloride, etoposide, ifosfamide, melphalan, vincristine sulfate, autologous hematopoietic stem cell transplantation, conventional surgery, radiation therapy
- Biological · Drug · Procedure + 1 more
- Lead sponsor
- University of Leicester
- Other
- Eligibility
- Up to 49 Years
- Enrollment
- 1,200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2001
- U.S. locations
- 88
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 80 more
- Conditions
- Malignant Melanoma
- Interventions
- CancerVax vaccine (CANVAXIN)
- Biological
- Lead sponsor
- CancerVax Corporation
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 670 participants
- Healthy volunteers
- Healthy volunteers not accepted
- U.S. locations
- 51
- States / cities
- Tucson, Arizona • Little Rock, Arkansas • Anaheim, California + 43 more
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- PF-02341066
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,069 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2015
- U.S. locations
- 140
- States / cities
- Birmingham, Alabama • Little Rock, Arkansas • Bakersfield, California + 71 more
- Conditions
- Solid Tumors
- Interventions
- Navlimetostat, Daraxonrasib, Temozolomide, Pumitamig, Pemetrexed, Carboplatin, Nab-paclitaxel, Gemcitabine, Paclitaxel, Cisplatin
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 254 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2032
- U.S. locations
- 16
- States / cities
- San Francisco, California • Aurora, Colorado • Atlanta, Georgia + 10 more
- Conditions
- Acute Undifferentiated Leukemia, Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative, Childhood Acute Lymphoblastic Leukemia, Childhood Acute Myeloid Leukemia, Childhood Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Childhood Solid Neoplasm, Chronic Lymphocytic Leukemia, Hairy Cell Leukemia, Juvenile Myelomonocytic Leukemia, Mast Cell Leukemia, Neoplasm of Uncertain Malignant Potential, Prolymphocytic Leukemia, Secondary Acute Myeloid Leukemia, T-Cell Large Granular Lymphocyte Leukemia
- Interventions
- Cytology Specimen Collection Procedure
- Other
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- Up to 30 Years
- Enrollment
- 2,545 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2018
- U.S. locations
- 175
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 132 more
- Conditions
- Anemia, Sickle Cell
- Interventions
- Rivipansel, Placebo
- Drug · Other
- Lead sponsor
- Biossil Inc.
- Industry
- Eligibility
- 6 Years and older
- Enrollment
- 345 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 126
- States / cities
- Mobile, Alabama • Little Rock, Arkansas • Oakland, California + 40 more
- Conditions
- Irritable Mood, Huntington's Disease
- Interventions
- SRX246, Placebo
- Drug
- Lead sponsor
- Azevan Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 106 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 22
- States / cities
- Birmingham, Alabama • Los Angeles, California • Sacramento, California + 19 more
- Conditions
- Onychomycosis
- Interventions
- IDP-108, Vehicle
- Drug
- Lead sponsor
- Dow Pharmaceutical Sciences
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 870 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2011
- U.S. locations
- 33
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • San Diego, California + 29 more
- Conditions
- Postoperative Gastrointestinal Dysfunction
- Interventions
- TAK-954 Placebo, TAK-954
- Drug
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 209 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 19
- States / cities
- Mobile, Alabama • Los Angeles, California • Orange, California + 14 more
- Conditions
- Metastatic Pancreatic Adenocarcinoma, Recurrent Pancreatic Carcinoma, Stage IV Pancreatic Cancer AJCC v6 and v7
- Interventions
- Fluorouracil, Irinotecan Hydrochloride, Laboratory Biomarker Analysis, Leucovorin Calcium, Veliparib
- Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 123 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2021
- U.S. locations
- 783
- States / cities
- Mobile, Alabama • Anchorage, Alaska • Hot Springs, Arkansas + 507 more
- Conditions
- Alzheimer Disease, Down Syndrome, Mild Cognitive Impairment
- Interventions
- Not listed
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 800 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2025
- U.S. locations
- 1
- States / cities
- Aurora, Colorado
- Conditions
- Metastatic Malignant Neoplasm in the Lung, Metastatic Osteosarcoma, Recurrent Osteosarcoma
- Interventions
- Dinutuximab, Laboratory Biomarker Analysis, Pharmacological Study, Sargramostim
- Biological · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- Up to 29 Years
- Enrollment
- 41 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2023
- U.S. locations
- 111
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 91 more
- Conditions
- HIV Infection
- Interventions
- Highly active antiretroviral therapy (HAART)
- Drug
- Lead sponsor
- International Maternal Pediatric Adolescent AIDS Clinical Trials Group
- Network
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 1,653 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2016
- U.S. locations
- 26
- States / cities
- Alhambra, California • Los Angeles, California • San Diego, California + 20 more
- Conditions
- Deep Vein Thrombosis Leg, DVT, Chronic DVT of Lower Extremity, Acute DVT of Lower Extremity
- Interventions
- ClotTriever
- Device
- Lead sponsor
- Inari Medical
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 499 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2024
- U.S. locations
- 43
- States / cities
- Birmingham, Alabama • Los Angeles, California • Orange, California + 37 more
- Conditions
- Clear Cell Renal Cell Carcinoma, Stage I Renal Cell Cancer AJCC v6 and v7, Stage II Renal Cell Cancer AJCC v7, Stage III Renal Cell Cancer AJCC v7
- Interventions
- Laboratory Biomarker Analysis, Placebo, Quality-of-Life Assessment, Sorafenib Tosylate, Sunitinib Malate
- Other · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 1,943 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2021
- U.S. locations
- 966
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 601 more
- Conditions
- Pulmonary Arterial Hypertension, Hypertension, Pulmonary
- Interventions
- Frespaciguat, Placebo to Frespaciguat
- Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 168 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 26
- States / cities
- La Jolla, California • Sacramento, California • San Francisco, California + 22 more
- Conditions
- Infant Growth, Infant Body Fat, Infant Gut Microbiome
- Interventions
- a high-protein complementary diet with meat, a high-protein complementary diet with dairy
- Behavioral
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 1 Month to 5 Months
- Enrollment
- 75 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014 – 2018
- U.S. locations
- 1
- States / cities
- Aurora, Colorado
- Conditions
- Brain Tumors
- Interventions
- Not listed
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 265 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2019
- U.S. locations
- 1
- States / cities
- Aurora, Colorado